Ultomiris – pharmaceutical daily

December 21, 2021 Off

Ultomiris accepted under FDA Priority Review in the US for adults with generalised myasthenia gravis

Astra Zeneca said Tuesday that Ultomiris regulatory submission has been accepted under FDA Priority Review in the US for adults with generalised myasthenia gravis, based on positive Phase III trial in which Ultomiris significantly improved functional activities as measured by Myasthenia Gravis-Activities of Daily Living Profile.

July 3, 2019 Off

ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

By BusinessWire

– ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients switching from SOLIRIS® (eculizumab) –

April 29, 2019 Off

Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

By BusinessWire

ULTOMIRIS has the potential to become the new standard of care forboth complement inhibitor-naïve patients and patients switching fromSOLIRIS (eculizumab) –